Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

被引：408

作者：

Jin, Liqing ^{[2
]}

Lee, Erwin M. ^{[1
]}

Ramshaw, Hayley S. ^{[3
]}

Busfield, Samantha J. ^{[4
]}

Peoppl, Armando G. ^{[2
]}

Wilkinson, Lucy ^{[5
]}

Guthridge, Mark A. ^{[3
]}

Thomas, Daniel ^{[3
]}

Barry, Emma F. ^{[3
]}

Boyd, Andrew ^{[5
]}

Gearing, David P. ^{[4
]}

Vairo, Gino ^{[4
]}

Lopez, Angel F. ^{[3
]}

Dick, John E. ^{[2
]}

Lock, Richard B. ^{[1
]}

机构：

[1] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW 2031, Australia

[2] Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada

[3] Inst Med & Vet Sci, Div Human Immunol, Ctr Canc Biol, Adelaide, SA 5000, Australia

[4] CSL Ltd, Melbourne, Vic 3052, Australia

[5] Queensland Inst Med Res, Brisbane, Qld 4029, Australia

来源：

CELL STEM CELL | 2009年 / 5卷 / 01期

关键词：

ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERLEUKIN-3; RECEPTOR; HEMATOPOIETIC-CELL; BONE-MARROW; SHORT-TERM; G-CSF; INTRAFEMORAL TRANSPLANTATION; GROWTH-FACTORS;

D O I：

10.1016/j.stem.2009.04.018

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Leukemia stem cells (LSCs) initiate and sustain the acute myeloid leukemia (AML) clonal hierarchy and possess biological properties rendering them resistant to conventional chemotherapy. The poor survival of AML patients raises expectations that LSC-targeted therapies might achieve durable remissions. We report that an anti-interleukin-3 (IL-3) receptor a chain (CD123)-neutralizing antibody (7133) targeted AML-LSCs, impairing homing to bone marrow (BM) and activating innate immunity of nonobese diabetic/severe-combined immunodeficient (NOD/SCID) mice. 7133 treatment profoundly reduced AML-LSC engraftment and improved mouse survival. Mice with preestablished disease showed reduced AML burden in the BM and periphery and impaired secondary transplantation upon treatment, establishing that AML-LSCs were directly targeted. 7133 inhibited IL-3-mediated intracellular signaling of isolated AML CD34(+) CD38(-) cells in vitro and reduced their survival. These results provide clear validation for therapeutic monoclonal antibody (mAb) targeting of AML-LSCs and for translation of in vivo preclinical research findings toward a clinical application.

引用

页码：31 / 42

页数：12

共 53 条

[11] In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides [J].

Fujii, Hisaki ;

Trudeau, Jacqueline D. ;

Teachey, David T. ;

Fish, Jonathan D. ;

Grupp, Stephan A. ;

Schultz, Kirk R. ;

Reid, Gregor S. D. .

BLOOD, 2007, 109 (05) :2008-2013

[12] Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies [J].

Graf, M ;

Hecht, K ;

Reif, S ;

Pelka-Fleischer, R ;

Pfister, K ;

Schmetzer, H .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (02) :89-106

[13] Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML) [J].

Guan, Y ;

Hogge, DE .

LEUKEMIA, 2000, 14 (12) :2135-2141

[14] Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML) [J].

Guan, YH ;

Gerhard, B ;

Hogge, DE .

BLOOD, 2003, 101 (08) :3142-3149

[15] Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch [J].

Guthridge, MA ;

Powell, JA ;

Barry, EF ;

Stomski, FC ;

McClure, BJ ;

Ramshaw, H ;

Felquer, FA ;

Dottore, M ;

Thomas, DT ;

To, B ;

Begley, CG ;

Lopez, AF .

EMBO JOURNAL, 2006, 25 (03) :479-489

[16] Site-specific serine phosphorylation of the IL-3 receptor is required for hemopoietic cell survival [J].

Guthridge, MA ;

Stomski, FC ;

Barry, EF ;

Winnall, W ;

Woodcock, JM ;

McClure, BJ ;

Dottore, M ;

Berndt, MC ;

Lopez, AF .

MOLECULAR CELL, 2000, 6 (01) :99-108

[17] The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-κB and induction of bcl-2 [J].

Guthridge, MA ;

Barry, EF ;

Felquer, FA ;

McClure, BJ ;

Stomski, FC ;

Ramshaw, H ;

Lopez, AF .

BLOOD, 2004, 103 (03) :820-827

[18] Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells [J].

Guzman, ML ;

Neering, SJ ;

Upchurch, D ;

Grimes, B ;

Howard, DS ;

Rizzieri, DA ;

Luger, SM ;

Jordan, CT .

BLOOD, 2001, 98 (08) :2301-2307

[19] Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells [J].

Hauswirth, A. W. ;

Florian, S. ;

Printz, D. ;

Sotlar, K. ;

Krauth, M. -T. ;

Fritsch, G. ;

Schernthaner, G. -H. ;

Wacheck, V. ;

Selzer, E. ;

Sperr, W. R. ;

Valent, P. .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (01) :73-82

[20] Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity [J].

Hope, KJ ;

Jin, LQ ;

Dick, JE .

NATURE IMMUNOLOGY, 2004, 5 (07) :738-743

← 1 2 3 4 5 6 →